Core Insights - The company, TianKang, has officially launched the development of its innovative drug CKBA for the treatment of Alzheimer's Disease (AD) [1] - TianKang is accelerating the research and development of AD indications while also preparing for Phase III clinical trials for CKBA in vitiligo and submitting applications for pediatric medications, as well as conducting Phase II/III clinical trials for rosacea [1] - The establishment of dedicated business units for certain indications aims to expedite the commercialization process post-approval [1] - Existing products and several upcoming generic drugs are expected to provide stable cash flow to support the company's innovative drug development [1] - Recent research findings on CKBA for AD have been published in the prestigious journal Nature Aging, highlighting key targets in the early metabolic inflammatory coupling pathways of AD and confirming CKBA's potential as a new generation small molecule candidate drug derived from natural products [1] - The research demonstrates a complete chain from mechanism study to translational application [1]
泰恩康正式启动CKBA药物治疗阿尔茨海默适应症研发